Research map: Effect of dose tapering policy on the prescription of advanced therapy for rheumatoid arthritis: a retrospective analysis of clinical and cost outcomes in Taiwan

Back to the article

Papers in this map

  1. SQUIRE 2.0 ( Standards for QUality Improvement Reporting Excellence) : revised publication guidelines from a detailed consensus process · Greg S. Ogrinc · 2015 · 2973 citations · Cited by this paper
  2. Ataluren for the treatment of people living with nonsense mutation Duchenne muscular dystrophy: a plain language summary of Study 041 · 2026 · Related
  3. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis · Jasvinder A. Singh · 2015 · 2811 citations · Cited by this paper
  4. Comparative effectiveness of oral antibiotics to treat uncomplicated urinary tract infections in male outpatients · 2026 · Related
  5. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis · Liana Fraenkel · 2021 · 1351 citations · Cited by this paper
  6. Access in all areas? A round-up of developments in market access and health technology assessment: part 13 · 2026 · Related
  7. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial · Josef S Smolen · 2013 · 358 citations · Cited by this paper
  8. Real-world clinical outcomes of patients with localized prostate cancer treated with radical prostatectomy in SEER-Medicare · 2026 · Related
  9. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis · Paul E. Emery · 2014 · 216 citations · Cited by this paper
  10. R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 26 · 2026 · Related
  11. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial · Noortje van Herwaarden · 2015 · 182 citations · Cited by this paper
  12. Transparency in positive airway pressure therapy trials: an evaluation of reporting quality · 2026 · Related
  13. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) · Bruno Fautrel · 2015 · 148 citations · Cited by this paper
  14. Treatment gaps in osteoporosis care following recurrent fractures: a nationwide cohort study · 2026 · Related
  15. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis · Ronald van Vollenhoven · 2015 · 135 citations · Cited by this paper
  16. Clinical outcomes of pressure-enabled drug delivery for trans-arterial chemoembolization and radioembolization · 2026 · Related
  17. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis · Isidoro González‐Álvaro · 2014 · 79 citations · Cited by this paper
  18. Readmissions and retreatment among stent-assisted endovascular coiling patients with unruptured intracranial aneurysm using ENTERPRISE ® 2 stent versus LVIS™ stent · 2026 · Related
  19. bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search · Lise M Verhoef · 2017 · 55 citations · Cited by this paper
  20. Comparing characteristics and outcomes between hospitalized adults on a pea protein or dairy/soy protein formulas: initial findings · 2026 · Related
  21. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study · Wietske Kievit · 2016 · 50 citations · Cited by this paper
  22. Adalimumab Dose Tapering in Psoriasis: Predictive Factors for Maintenance of Complete Clearance · Katharina Hansel · 2017 · 50 citations · Cited by this paper
  23. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis · Yoshiya Tanaka · 2019 · 38 citations · Cited by this paper
  24. Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology · for the Hong Kong Society of Rheumatology · 2019 · 34 citations · Cited by this paper
  25. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial · Antoine Vanier · 2017 · 31 citations · Cited by this paper
  26. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis · Josef S Smolen · 2019 · 28 citations · Cited by this paper
  27. Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review · Chak Sing Lau · 2017 · 26 citations · Cited by this paper
  28. Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study · Shunsuke Mori · 2019 · 26 citations · Cited by this paper
  29. Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives · Suz Jack Chan · 2019 · 18 citations · Cited by this paper
  30. Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis · Benjamin Birkner · 2020 · 17 citations · Cited by this paper
  31. Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial · Delphine Bertrand · 2021 · 16 citations · Cited by this paper
  32. Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance Database · Bruce C. M. Wang · 2016 · 14 citations · Cited by this paper
  33. Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients · Daniel Aletaha · 2017 · 11 citations · Cited by this paper
  34. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature · Der‐Yuan Chen · 2017 · 10 citations · Cited by this paper
  35. Clinical and radiologic analysis of on-demand use of etanercept for disease flares in patients with rheumatoid arthritis for 2 years · Kentaro Inui · 2018 · 7 citations · Cited by this paper
  36. Dose down‐titration of biological disease‐modifying antirheumatic drugs in daily clinical practice: Shared decision‐making and patient treatment preferences in Japanese patients with rheumatoid arthritis · Takaaki Komiya · 2019 · 3 citations · Cited by this paper
  37. Untitled · Cited by this paper

Source: OpenAlex (CC0)